BioMaxima S.A. (WSE: BMX)
Poland
· Delayed Price · Currency is PLN
14.75
+0.45 (3.15%)
Sep 27, 2024, 5:00 PM CET
BioMaxima Revenue
BioMaxima had revenue of 11.53M PLN in the quarter ending March 31, 2024, with 4.12% growth. This brings the company's revenue in the last twelve months to 47.24M, down -22.99% year-over-year. In the year 2023, BioMaxima had annual revenue of 46.79M, down -67.48%.
Revenue (ttm)
47.24M
Revenue Growth
-22.99%
P/S Ratio
1.33
Revenue / Employee
410.80K
Employees
115
Market Cap
61.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.79M | -97.08M | -67.48% |
Dec 31, 2022 | 143.87M | 64.78M | 81.91% |
Dec 31, 2021 | 79.09M | 17.81M | 29.06% |
Dec 31, 2020 | 61.28M | 30.67M | 100.19% |
Dec 31, 2019 | 30.61M | -1.41M | -4.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Krka, d. d. | 8.06B |
NEUCA S.A. | 12.13B |
Sopharma AD | 4.35B |
Synektik Spólka Akcyjna | 618.67M |
Celon Pharma S.A. | 206.81M |
Ryvu Therapeutics S.A. | 82.39M |
Voxel S.A. | 476.19M |
Selvita S.A. | 329.02M |